Table 1.
Patient characteristics
| Characteristic | No. (%) |
|---|---|
| T stage | |
| Tis | 5 (10) |
| T1 | 39 (76) |
| T2 | 6 (12) |
| T3 | 1 (2) |
| N stage | |
| N0 | 32 (63) |
| N+ | 15 (29) |
| Nx | 4 (8) |
| Locationa) | |
| UOQ | 29 (57) |
| UIQ | 12 (24) |
| LOQ | 4 (8) |
| LIQ | 2 (4) |
| Central | 3 (6) |
| Surgery | |
| WE only | 4 (8) |
| WE+SLNBx | 30 (59) |
| WE+ALND | 14 (27) |
| WE with nipple excision | 3 (6) |
| Radiotherapy dose | |
| WBRT 50.4 Gy | 8 (16) |
| WBRT 50.4 Gy+boost 9-10 Gy | 39 (76) |
| WBRT 50.4 Gy+boost 14.4-16 Gy | 4 (8) |
| Radiotherapy technique | |
| Tangential field | 41 (80) |
| Tangential field with supraclavicular field | 10 (20) |
| Chemotherapy | |
| None | 22 (43) |
| AC±D | 18 (35) |
| CMF | 7 (14) |
| Others | 4 (8) |
| Total | 51 (100) |
UOQ, upper outer quadrant; UIQ, upper inner quadrant; LOQ, lower outer quadrant; LIQ, lower inner quadrant; WE, wide excision; SLNBx, sentinel lymph node biopsy; ALND, axillary lymph node biopsy; WBRT, whole breast radiotherapy; AC, cyclophosphamide and doxorubicin; D, docetaxel; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil.
a)
Available data only.